628 related articles for article (PubMed ID: 19908287)
1. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.
Rojo AI; Innamorato NG; Martín-Moreno AM; De Ceballos ML; Yamamoto M; Cuadrado A
Glia; 2010 Apr; 58(5):588-98. PubMed ID: 19908287
[TBL] [Abstract][Full Text] [Related]
2. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
Chung YC; Kim SR; Jin BK
J Immunol; 2010 Jul; 185(2):1230-7. PubMed ID: 20566832
[TBL] [Abstract][Full Text] [Related]
3. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
[TBL] [Abstract][Full Text] [Related]
4. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
[TBL] [Abstract][Full Text] [Related]
5. Microglial activation and age-related dopaminergic neurodegeneration in MPTP-treated SAMP8 mice.
Liu J; Wang MW; Gu P; Ma QY; Wang YY; Geng Y; Yuan ZY; Cui DS; Zhang ZX; Ma L; Zhang BH; Zhou MG; Zhu AP
Brain Res; 2010 Jul; 1345():213-20. PubMed ID: 20546706
[TBL] [Abstract][Full Text] [Related]
6. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
Tripanichkul W; Sripanichkulchai K; Finkelstein DI
Brain Res; 2006 Apr; 1084(1):28-37. PubMed ID: 16564034
[TBL] [Abstract][Full Text] [Related]
7. In vivo modulation of the Parkinsonian phenotype by Nrf2.
Burton NC; Kensler TW; Guilarte TR
Neurotoxicology; 2006 Dec; 27(6):1094-100. PubMed ID: 16959318
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha.
Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
FASEB J; 2006 Apr; 20(6):670-82. PubMed ID: 16581975
[TBL] [Abstract][Full Text] [Related]
9. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.
Sriram K; Miller DB; O'Callaghan JP
J Neurochem; 2006 Feb; 96(3):706-18. PubMed ID: 16405514
[TBL] [Abstract][Full Text] [Related]
10. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum.
Ferger B; Leng A; Mura A; Hengerer B; Feldon J
J Neurochem; 2004 May; 89(4):822-33. PubMed ID: 15140182
[TBL] [Abstract][Full Text] [Related]
11. Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model.
Kang JM; Park HJ; Choi YG; Choe IH; Park JH; Kim YS; Lim S
Brain Res; 2007 Feb; 1131(1):211-9. PubMed ID: 17173870
[TBL] [Abstract][Full Text] [Related]
12. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.
Kalkonde YV; Morgan WW; Sigala J; Maffi SK; Condello C; Kuziel W; Ahuja SS; Ahuja SK
Brain Res; 2007 Jan; 1128(1):1-11. PubMed ID: 17126305
[TBL] [Abstract][Full Text] [Related]
13. Defining "neuroinflammation".
O'Callaghan JP; Sriram K; Miller DB
Ann N Y Acad Sci; 2008 Oct; 1139():318-30. PubMed ID: 18991877
[TBL] [Abstract][Full Text] [Related]
14. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity.
McLaughlin P; Zhou Y; Ma T; Liu J; Zhang W; Hong JS; Kovacs M; Zhang J
Glia; 2006 Apr; 53(6):567-82. PubMed ID: 16419087
[TBL] [Abstract][Full Text] [Related]
15. MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice.
Costa G; Frau L; Wardas J; Pinna A; Plumitallo A; Morelli M
Mov Disord; 2013 Dec; 28(14):1957-65. PubMed ID: 24108425
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.
Knyihár-Csillik E; Csillik B; Pákáski M; Krisztin-Péva B; Dobó E; Okuno E; Vécsei L
Neuroscience; 2004; 126(4):899-914. PubMed ID: 15207325
[TBL] [Abstract][Full Text] [Related]
17. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
[TBL] [Abstract][Full Text] [Related]
18. Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.
Kurkowska-Jastrzebska I; Bałkowiec-Iskra E; Ciesielska A; Joniec I; Cudna A; Zaremba MM; Członkowski A; Członkowska A
Int Immunopharmacol; 2009 Jun; 9(6):781-91. PubMed ID: 19286483
[TBL] [Abstract][Full Text] [Related]
19. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease.
Joglar B; Rodriguez-Pallares J; Rodriguez-Perez AI; Rey P; Guerra MJ; Labandeira-Garcia JL
J Neurochem; 2009 Apr; 109(2):656-69. PubMed ID: 19245663
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Sugama S; Wirz SA; Barr AM; Conti B; Bartfai T; Shibasaki T
Neuroscience; 2004; 128(2):451-8. PubMed ID: 15350655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
